Medical technology company Teleflex (NYSE:TFX) in Q4 CY2025, with sales falling 28.5% year on year to $569 million. Its non-GAAP profit of $1.93 per share was 48.4% below analysts’ consensus estimates ...

Q4 2025 earnings call recap: divestitures, $1.8B proceeds, $1B buyback, 2026 EPS $6.25–$6.55, risks & outlook—read now.

Teleflex (NYSE: TFX) reported fourth quarter EPS of $1.93, $1.86 worse than the analyst estimate of $3.79. Revenue for the quarter came in at $568.98M versus the c ...

Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 26, ...

Teleflex TFX posted solid fourth-quarter performance, ending the year on a stable note. On one hand, currency was a major headwind across all segments this fiscal year, and supply chain and staffing ...

Acquisition will further advance Teleflex’s Interventional portfolio with a differentiated global suite of coronary vascular and peripheral vascular intervention devices WAYNE, Pa., Feb. 27, 2025 ...

Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the year ended December 31, 2025.

Investing.com -- Shares of Teleflex (NYSE:TFX) fell 8.8% to $102 in premarket trading on Thursday after the medical device maker reported fourth quarter results that missed Wall Street expectations.